Vancomycin→seeTABLE 2p. 847 (nephrotoxicity),TABLE 19p. 851
(ototoxicity)
Vandetanib→seeTABLE 9p. 849 (QT-interval prolongation)
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)are predicted to decrease the exposure
tovandetanib. Avoid.oStudy
▶Vandetanibis predicted to increase the risk of bleeding events
when given withcoumarins.rTheoretical
▶Vandetanibslightly increases the exposure todigoxin. Monitor
ECG and adjust dose.oStudy
▶Enzalutamideis predicted to decrease the exposure to
vandetanib. Avoid.oStudy
▶Vandetanibslightly increases the exposure tometformin.
Monitor and adjust dose.oStudy
▶Mitotaneis predicted to decrease the exposure tovandetanib.
Avoid.oStudy
▶Vandetanibis predicted to increase the risk of bleeding events
when given withphenindione.rTheoretical
▶Rifampicinis predicted to decrease the exposure to
vandetanib. Avoid.oStudy
Vardenafil→see phosphodiesterase type-5 inhibitors
Varicella-zoster vaccine→see live vaccines
Vecuronium→see neuromuscular blocking drugs, non-depolarising
Vedolizumab→see monoclonal antibodies
Velpatasvir
▶Velpatasviris predicted to increase the exposure toaliskiren.
rTheoretical
▶Antacidsare predicted to decrease the concentration of
velpatasvir. Separate administration by 4 hours.o
Theoretical
▶Antiarrhythmics(amiodarone)are predicted to increase the
concentration ofvelpatasvir. Avoid or monitor.o
Theoretical
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)are predicted to moderately decrease
the exposure tovelpatasvir. Avoid.rStudy
▶Antiepileptics(oxcarbazepine)are predicted to decrease the
exposure tovelpatasvir. Avoid.rTheoretical
▶Velpatasviris predicted to increase the exposure to
antihistamines, non-sedating(fexofenadine).rTheoretical
▶Bosentanis predicted to decrease the exposure tovelpatasvir.
Avoid.oTheoretical
▶Calcium salts(calcium carbonate)are predicted to decrease the
concentration ofvelpatasvir. Separate administration by
4 hours.oAnecdotal
▶Velpatasviris predicted to increase the exposure tocolchicine.
rTheoretical
▶Velpatasviris predicted to increase the exposure to
dabigatran.rTheoretical
▶Velpatasviris predicted to increase the exposure todigoxin.
rStudy
▶Velpatasviris predicted to increase the exposure toedoxaban.
rTheoretical
▶Efavirenzis predicted to decrease the exposure tovelpatasvir.
Avoid.oTheoretical
▶Enzalutamideis predicted to moderately decrease the
exposure tovelpatasvir. Avoid.rStudy
▶Velpatasviris predicted to increase the exposure to
everolimus.rTheoretical
▶H 2 receptor antagonistsare predicted to decrease the
concentration ofvelpatasvir. Adjust dose, seesofosbuvir with
velpatasvir.oStudy
▶Velpatasviris predicted to increase the exposure to
loperamide.rTheoretical
▶Mitotaneis predicted to moderately decrease the exposure to
velpatasvir. Avoid.rStudy
▶Nevirapineis predicted to decrease the exposure tovelpatasvir.
Avoid.oTheoretical
▶Proton pump inhibitorsare predicted to decrease the
concentration ofvelpatasvir. Adjust dose, seesofosbuvir with
velpatasvir.oStudy
▶Rifampicinis predicted to moderately decrease the exposure
tovelpatasvir. Avoid.rStudy
▶Velpatasviris predicted to increase the exposure tosirolimus.
rTheoretical
▶St John’sWortis predicted to decrease the exposure to
velpatasvir. Avoid.oTheoretical
▶Velpatasviris predicted to increase the exposure tostatins
(atorvastatin, simvastatin). Monitor side effects and adjust
dose.rTheoretical
▶Velpatasvirincreases the exposure tostatins(rosuvastatin).
Adjustrosuvastatindose and monitor side effects,p. 133.
rStudy
▶Velpatasviris predicted to increase the exposure totaxanes
(paclitaxel).rTheoretical
▶Velpatasviris predicted to increase the exposure totenofovir
disoproxil.rStudy
▶Velpatasviris predicted to increase the exposure totopotecan.
rTheoretical
Vemurafenib→seeTABLE 9p. 849 (QT-interval prolongation)
▶Vemurafenibis predicted to increase the exposure toafatinib.
Separate administration by 12 hours.oStudy
▶Vemurafenibis predicted to increase the exposure toaliskiren.
Use with caution and adjust dose.oTheoretical
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)are predicted to decrease the exposure
tovemurafenib. Avoid.rTheoretical
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to increase the exposure tovemurafenib.r
Theoretical→Also seeTABLE 9p. 849
▶Vemurafenibis predicted to increase the exposure tobeta
blockers, non-selective(nadolol).oStudy
▶Cobicistatis predicted to increase the exposure to
vemurafenib.rTheoretical
▶Vemurafenibis predicted to increase the exposure to
colchicine. Avoid or adjustcolchicinedose.rTheoretical
▶Vemurafenibincreases the exposure todabigatran. Use with
caution and adjust dose.rTheoretical
▶Vemurafenibis predicted to slightly increase the exposure to
edoxaban.rTheoretical
▶Enzalutamideis predicted to decrease the exposure to
vemurafenib. Avoid.rTheoretical
▶Vemurafenibis predicted to increase the exposure toerlotinib.
oTheoretical
▶Vemurafenibis predicted to increase the exposure to
fidaxomicin. Avoid.oStudy
▶HIV-protease inhibitorsare predicted to increase the exposure
tovemurafenib.rTheoretical→Also seeTABLE 9p. 849
▶Idelalisibis predicted to increase the exposure tovemurafenib.
rTheoretical
▶Macrolides(clarithromycin)are predicted to increase the
exposure tovemurafenib.rTheoretical→Also seeTABLE 9
p. 849
▶Mitotaneis predicted to decrease the exposure tovemurafenib.
Avoid.rTheoretical
▶Vemurafenibis predicted to increase the exposure to
nintedanib.oStudy
▶Vemurafenibis predicted to increase the exposure to
panobinostat. Adjust dose.oTheoretical→Also see
TABLE 9p. 849
▶Rifampicinis predicted to decrease the exposure to
vemurafenib. Avoid.rTheoretical
▶Vemurafenibis predicted to increase the exposure to
ticagrelor. Use with caution or avoid.rStudy
▶Vemurafenibis predicted to increase the exposure to
topotecan.rStudy
▶Vemurafenibis predicted to increase the concentration of
trametinib.oTheoretical
▶Vemurafenibis predicted to increase the exposure to
venetoclax. Avoid or monitor for toxicity.rTheoretical
Venetoclax
FOOD AND LIFESTYLEAvoid Seville (bitter orange) and star fruit
as they might increase the exposure to venetoclax.
▶Antiarrhythmics(amiodarone)are predicted to increase the
exposure tovenetoclax. Avoid or monitor for toxicity.r
Theoretical
▶Antiarrhythmics(dronedarone)are predicted to increase the
exposure tovenetoclax. Avoid moderate inhibitors of CYP3A4
or adjustvenetoclaxdose.rStudyBNFC 2018 – 2019 Vancomycin—Venetoclax 1007
Interactions|Appendix 1A1